ReviewAJR. American journal of roentgenology2024
Management of Patients With a Negative Multiparametric Prostate MRI Examination:
Review in AJR. American journal of roentgenology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- The evolving PI-RADS paradigm.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.Insights into imaging · 2026Article
- Article
- Letter to the editor regarding "The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions a multicenter retrospective study".International journal of surgery (London, England) · 2026Article
- AI and human interactions in prostate cancer diagnosis using MRI.European radiology · 2025Review
- AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study.European radiology · 2025Article
- Refining the need for prostate biopsy and the evolving role of MRI.European radiology · 2025Article
- Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naive Men: PI-RADS Steering Committee, Version 1.0.Radiology · 2025Review
- Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.JAMA oncology · 2025Article
- Predicting uninformative prostate magnetic resonance imaging sequences: a hypothesis-generating pilot study.Radiologia brasileiraArticle
- Magnetic resonance imaging/ultrasound fusion-guided targeted biopsy and ultrasound-guided systematic biopsy for prior negative prostate biopsy: A meta-analysis.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Multiparametric MRI (mpMRI) of the prostate aids risk stratification of patients with elevated PSA levels. Although most clinically significant prostate cancers are detected by mpMRI, insignificant cancers are less evident. Thus, multiple international prostate cancer guidelines now endorse routine use of prostate MRI as a secondary screening test before prostate biopsy. Nonetheless, management of patients with negative mpMRI results (defined as PI-RADS category 1 or 2) remains unclear. This
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.